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1 |  INTRODUCTION
Aortic stenosis is the commonest degenerative valve disor-
der in the west. Transcatheter interventions have introduced 
a new option of valve replacement in high‐risk patients. An 
outstanding question is the management of degenerative 
valve disease in the heart transplant (HTx) population given 
their unique combination of comorbidity, lack of representa-
tion in studies to derive cardiothoracic surgical risk scoring 
and technical difficulties of redo surgery. Here, we present 
a 77‐year‐old man undergoing transcatheter aortic valve im-
plantation (TAVI) for degenerative bicuspid aortic (BAV) 
valve stenosis 23 years after HTx.
Aortic valve stenosis (AS) is by far the commonest valvu-
lar disease in the aging population. In addition, BAV is the 
most prevalent congenital valvular abnormality. It is consid-
ered a significant risk factor for premature aortic valve dis-
ease, most commonly AS.1 BAV disease was an exclusion 
criterion in fundamental clinical trials to test the safety and 
efficacy of TAVI, largely because of the unique morpholog-
ical features and associated aortic pathology of this condi-
tion.2,3 Limited data exist for outcomes from TAVI in BAV 
and, despite promising single‐center series,4,5 a recently pub-
lished multi‐center series raised concerns about the excess of 
paravalvular regurgitation.6
There is no doubt that the increasing longevity of HTx 
recipients accompanied by the older age at transplantation 
and aging donor population led to an increase in the prev-
alence of degenerative valvular disease. This increase, in 
this unique population, rendered optimal treatment strategy 
unknown in the context of their specific comorbidity.
We present our experience of a 77‐year‐old man present-
ing with severe allograft bicuspid aortic stenosis 23 years 
after HTx.
2 |  CASE PRESENTATION
A 77‐year‐old man attended our services with exertional 
dyspnoea secondary to aortic valve stenosis. He received an 
orthotopic heart transplantation (HTx) in 1994 for idiopathic 
dilated cardiomyopathy (DCM). Unfortunately, we have no 
records of the patient’s transplant operative data given the 
fact that his procedure was done 23 years ago. He remained 
asymptomatic during follow‐up except for paroxysmal atrial 
flutter for which he received a single chamber pacemaker 
in 2008 and later, atrial flutter ablation in 2010. Patient was 
adherent to his medication regimen and did not show any 
signs of transplant rejection on several cardiac biopsies. His 
post‐transplant cardiovascular risk factors included systemic 
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hypertension, dyslipidaemia, and stable stage 4 chronic renal 
dysfunction (eGFR 23 mL/min/1.73 m2). Serial transthoracic 
echocardiography (TTE) performed in our institution showed 
progressive degenerative aortic valve disease.
At presentation, his TTE showed degenerative bicuspid 
aortic valve with fusion of the right and left coronary cusps 
by an incomplete raphe. The appearance of the valve was 
consistent with severe aortic stenosis which was confirmed 
by hemodynamic Doppler assessment that revealed a peak 
gradient of 65 mm Hg, aortic valve area of 0.9 cm2 derived 
from the continuity equation and a dimensionless velocity 
index (DVI) of 0.24. Left ventricular function was normal 
with an ejection fraction (EF) of 59% by Simpson’s method. 
Further evaluation of the aortic valve and aorto‐iliac anat-
omy was pursued by a Multi‐detector computed tomography 
(MDCT). It confirmed the morphology of a heavily calcific 
BAV, the absence of associated aortopathy, and suitability for 
transfemoral approach. The maximal aortic annulus dimen-
sion was measured as 25 mm with an aortic root diameter 
of 32 mm at the level of the sinuses of Valsalva. Coronary 
angiography was performed to screen for cardiac allograft 
vasculopathy (CAV) which did not show any evidence of ob-
structive coronary disease.
In addition, he was noted on admission to be bradycardic 
with episodes of second‐degree mobitz type 2 atrio‐ventric-
ular (AV) heart block. Electrophysiology service was con-
sulted and decided the need to upgrade his pacemaker to a 
dual‐chamber system following the TAVI procedure.
His case was discussed at the Heart Valve Team meet-
ing with a consensus that TAVI would be the optimal inter-
vention strategy being a high‐risk surgical candidate with a 
Society of Thoracic Surgery (STS) predicted risk of 30 days 
mortality of 7.035%.
The TAVI procedure was performed according to the stan-
dard local TAVI protocol. Vascular access was obtained with 
ultrasound guidance under local anesthesia and conscious 
sedation. Heparin (6000 units) was given intraoperatively 
to achieve an activated clotting time (ACT) greater than 
250 seconds. A balloon expandable 29 mm Edwards Sapien 
3 transcatheter heart valve (Edwards Lifesciences, Irvine, 
CA, USA) was advanced via the right femoral artery through 
the calcified, transplanted native aortic valve without prior 
balloon aortic valvuloplasty. Final positioning was confirmed 
by fluoroscopic guidance. Under rapid ventricular pacing, by 
temporary pacing wire via the left femoral vein, expansion 
of the prosthesis over the stenotic valve was accomplished 
with excellent results and no immediate complications. The 
total amount of contrast used was 60 mL and subsequent 
renal function tests were stable. His pacemaker was elec-
tively upgraded to a dual‐chamber system the following day 
as planned earlier due to pre‐existing high degree heart block. 
Pre‐discharge TTE revealed a well‐positioned aortic valve 
prosthesis with a peak and mean trans‐prosthesis gradients 
of 14 mm Hg and 12 mm Hg respectively. There was no evi-
dence of valvular or paravalvular regurgitation on color flow 
Doppler and the LV systolic function remained normal.
Patient showed immediate symptomatic and hemo-
dynamic improvement and was discharged from hospital 
48 hours post index procedure. He was maintained on his reg-
ular medication including the immunosuppressive therapy. 
At the routine 1‐month clinic follow‐up the patient was doing 
well and did not report any symptoms with no limitation of 
his physical activity (NYHA 1).
3 |  DISCUSSION
The first‐in‐man TAVI was performed in 2002 by Alain 
Cribier in France.7 Ever since excellent achievements have 
been made in the field of TAVI saving lots of lives. The 
PARTNER trials comparing TAVI with SAVR in high‐risk 
severe aortic stenosis patients were the cornerstone for TAVI, 
which showed similar survival rates at 1 year,8 improved 
valve hemodynamic at 2 years, reduction in symptoms, death 
rates, and hospitalizations.7,9 TAVI, however, showed more 
frequent paravalvular regurgitation and increased late mor-
tality.7,9 Although TAVI has been limited to high‐risk and 
inoperable patients, carefully selected younger patients may 
benefit from this approach if advantages of the TAVI out-
weigh the results expected from conventional SAVR.10 HTx 
recipients with aortic valve disease may be considered eligi-
ble candidates for TAVI because of patient‐specific and pro-
cedure‐specific features.
In 2010 Seiffert et al reported the first case of TAVI in 
a HTx recipient. The patient was a high‐risk 81 years old 
who underwent a TAVI for severe AS 15 years post‐HTx 
due to end‐stage DCM. Pre‐operative assessment revealed a 
severely depressed LVEF of 30% secondary to concomitant 
CAV. Percutaneous coronary intervention (PCI) for an 80% 
stenosis of the LAD artery was carried out and TTE post in-
tervention showed improvement of LV systolic function with 
an EF of 50%. The author also mentioned that the mean aortic 
pressure gradient was 23 mm Hg with an effective orifice area 
of 0.6 cm2 which is consistent with a paradoxical low gradi-
ent AS. The author did not clarify the underlying morphology 
of the AV or if further investigation was performed to con-
firm the presence of severe AS such as low‐dose Dobutamine 
stress echocardiography (DSE). Transapical approach was 
adopted due to extensive calcification of both ascending and 
descending aorta as well as kinking of the iliac arteries. A 
26 mm Edward Sapien THV was implanted successfully with 
only trivial paravalvular regurgitation.11
In the same year, Bruschi et al reported a 67 years old 
man who had a transfemoral TAVI for severe AS that devel-
oped 9 years after his HTx. Pre‐operative TTE showed a peak 
transvalvular pressure gradient of 87 mm Hg, indexed AVA 
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of 0.5 cm2/m2 and severe LV systolic dysfunction (EF 35%). 
A 29 mm CoreValve prosthesis (Medtronic, Minneapolis, 
MN) was deployed with excellent results and only mild para-
valvular regurgitation which was seen on the pre‐discharge 
TTE.12
TAVI was not only utilized in high‐risk HTx recipients 
with severe AS but included patients with significant aortic 
regurgitation (AR). Zanuttini et al reported the first case of 
a transfemoral TAVI performed on a high‐risk 75‐year‐old 
HTx recipient for severe degenerative AR. The patient was 
transplanted 14 years earlier due to end‐stage DCM as a 
result of previous aortic and mitral valve replacement. The 
pre‐operative TTE showed mildly dilated LV, moderate LV 
dysfunction (EF 40%) and a thickened tri‐leaflet AV cusps. 
Doppler study demonstrated severe central jet of AR as a re-
sult of a deformed and retracted left coronary cusp. Similar 
to Bruschi et al case, a 29 mm CoreValve was used based on 
the decision of the heart team to proceed to TAVI for the very 
high‐risk profile (EuroSCORE 36%). His hospital course was 
complicated by a third‐degree AV block 48 hours post‐TAVI 
for which he received a permanent pacemaker. He also devel-
oped lower respiratory infection that was successfully treated 
with antibiotics. Pre‐discharge TTE showed a well function-
ing prosthetic valve, with peak and mean pressure gradients 
of 16 mm Hg and 10 mm Hg, respectively, and a mild para-
valvular regurgitation.13
Furthermore, in 2013, Praetere et al reported a 77‐year‐
old patient who received his HTx in 1993 for end‐stage 
ischemic cardiomyopathy. Post transplantation the patient 
developed severe CAV, which lead to multiple PCIs in 1996, 
1997 and 2003. Despite revascularization he remained 
symptomatic with reduced exercise tolerance. Baseline TTE 
showed an AVA of 1.0 cm2, severely depressed LV systolic 
function with an EF of <25% and evidence of classical low 
flow, low gradient AS. Additional testing with low‐dose DSE 
failed to confirm the true severity of AS and a decision was 
to proceed with balloon aortic valvuloplasty (BAV) to eval-
uate its effects on symptoms and LVEF. A modest improve-
ment in the LVEF (up to 30%) and in patients’ symptoms 
were noted, however, these improvements were transient and 
symptoms relapsed after 7 months. This transient improve-
ment with BAV justified the decision to proceed with TAVI 
which was achieved using a 23 mm Edwards Sapien valve. 
TTE post‐TAVI demonstrated a normal functioning valve, 
peak and mean pressure gradients were 18 and 11 mm Hg 
respectively, stable LVEF of 30% and no paravalvular aortic 
regurgitation.14
Ahmad et al reported a TAVI in a 25‐year‐old female who 
received an urgent HTx at the age of 11 years due to severe 
congestive heart failure. She had corrective operations for 
multiple ventricular septal defects at the age of 1 and 3 years 
of age. Interestingly, the donor heart was from a 62‐year‐old 
female with pre‐existing moderate coronary artery disease 
and mild AS. After 14 years, she developed exercise‐limiting 
symptoms with a NYHA III class. TTE showed a heavily cal-
cific tri‐leaflet AV with combination of severe AS (Peak gra-
dient 77 mm Hg, mean gradient 44 mm Hg, AVA <1.0 cm2) 
and severe AR with a preserved LVEF. Patient underwent 
transfemoral TAVI with a 23 mm Edwards Sapien 3 valve 
with no complication. Her symptoms improved dramatically 
and post‐operative TTE showed normal functioning prosthe-
sis with peak gradient of 20 mm Hg, mean gradient 11 mm 
Hg and no paravalvular regurgitation.15
In December of the same year, Herrmann et al presented 
a 73 years old male who had a successful transfemoral TAVI 
with a 26 mm Edwards Sapien 3 transcatheter heart valve 
13 years post heart transplant. The pre‐operative TTE showed 
a severely stenosed BAV with a mean transvalvular pressure 
gradient of 43 mm Hg and a calculated AVA of 0.58 cm2. The 
heart valve team opted for TAVI being a high‐risk surgical 
candidate with a STS predicted risk of 30 days mortality of 
8.024%. Post‐operative TTE revealed a peak and mean pres-
sure gradient of 27 mm Hg and 13 mm Hg respectively with 
no paravalvular regurgitation.16
As a consequence of worldwide heart donor paucity and 
increased demand, marginal donors are often accepted partic-
ularly in patients with an urgent call for HTx. The marginal 
donor is often characterized with higher age and comorbid-
ities such as diabetes, hypertension and even mild valvular 
heart disease. Survival rates after HTx have increased sig-
nificantly which might increase the likelihood for develop-
ment of significant age‐related valvular disease in the HTx 
population.
Although cardiac surgery after heart transplantation is 
considered a safe and effective option as stated by Goerler 
et al17 in 2010, the author also highlighted the increased risk 
of bleeding owing to marked adhesions after previous sur-
gical procedures, as well as the increased risk of renal fail-
ure, infection and wound healing disorders due to long‐term 
immunosuppression. However, the author did not take into 
consideration the risks associated with general anesthesia, 
prolonged hospital admission, nosocomial infection and the 
cost‐effectiveness impact on the healthcare system which are 
considerably lower with TAVI.
Extensive literature search showed lack of data studying 
the safety and efficacy of TAVI in HTx recipients specifically 
in the setting of BAV disease.
4 |  CONCLUSION
TAVI has been rarely performed in HTx patients with no 
available data comparing TAVI versus SAVR in this iso-
lated population. Indeed, in this case, conventional surgery 
would have carried a higher risk of complication of a redo 
surgery, profound renal failure and poor wound healing due 
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to immunosuppressive treatment. The current paper dem-
onstrates a successful transfemoral TAVI in a HTx recipi-
ent. To our knowledge, this is the seventh case worldwide 
reporting TAVI in HTx recipient, the second in a bicus-
pid aortic valve and the first case receiving a TAVI after 
23 years post‐HTx, which is considered the longest dura-
tion reported so far. This emphasizes the need for further 
studies to assess safety and efficacy of TAVI in this unique 
population with increasing survival durations owing to the 
advances in medicine.
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